Menopause hormone therapy: what the FDA label changes mean

Menopause treatment begins with something concrete: how you feel and what is disrupting your life. Hormone therapy can reduce troublesome hot flashes and vaginal symptoms, and it can help protect bone in appropriate patients. Those are valuable benefits in their own right. [5] [6] [7]

The FDA's changes to US hormone-therapy labels invite a more precise discussion of those benefits and the risks. Understanding them means looking at the treatment a woman might actually use.

What changed in the US warnings

The FDA began the revision process in November 2025 and approved changes for an initial six products in February 2026. Broad cardiovascular, breast-cancer and probable-dementia statements were removed from the prominent boxed warnings. Relevant precautions remain elsewhere in the prescribing information, and some products retain a boxed warning about the uterine lining. [1] [2] [3]

A warning change can improve a conversation that has often treated all hormone therapy as one thing. A vaginal treatment for dryness, a skin-applied estrogen for hot flashes and an oral estrogen-progesterone combination have different purposes and exposures.

For example, the updated Divigel label retains a warning about endometrial cancer when systemic estrogen is used without suitable protection in someone with a uterus. Bijuva and Estring no longer have boxed warnings, but still have precautions and circumstances in which they should not be used. These are examples of the distinctions, rather than a recommendation for one brand. [4] [5] [6]

The changes concern US prescribing information. European and Czech product information follows its own regulatory process.

Match the treatment to the symptom

Systemic hormone therapy reaches tissues throughout the body and can be effective for hot flashes and night sweats. Local vaginal estrogen targets symptoms such as dryness and discomfort. Low-dose local treatment generally produces less whole-body exposure, although absorption is not zero. It should not be expected to deliver every effect of systemic treatment. [5] [6]

Whether you have a uterus changes the plan. Systemic estrogen can stimulate its lining, so appropriate protection, commonly a progestogen, is usually needed. After hysterectomy this is generally unnecessary, with some exceptions. Low-dose vaginal estrogen follows a different approach and does not routinely require a progestogen under European guidance. [4] [7]

Bone protection can also be part of the decision. Hormone therapy helps prevent bone loss and reduces fracture risk, but the right choice depends on your overall situation and the alternatives. Not every menopause product has the same approved bone-health use. [7]

Why timing and health history matter

For many women considering systemic treatment, the balance is more favorable before age 60 or within ten years of menopause. This is a starting point for discussion, not a guarantee. Starting for the first time later in life is also different from reviewing a treatment that has worked well for years. [4] [5] [7]

The clinician needs to know about unexplained bleeding, previous breast cancer, blood clots, stroke, heart attack, liver disease and other relevant conditions. These can change or rule out particular choices. Estrogen through the skin may carry a lower vein-clot risk than oral estrogen, based largely on observational evidence, but a patch or gel does not remove every risk. [4] [7]

Early loss of ovarian function is a distinct situation. For premature ovarian insufficiency, hormone replacement is generally supported until at least the usual age of menopause unless contraindicated. Evidence about starting treatment much later should not obscure the needs of younger women replacing hormones lost unusually early. [13]

What the major studies add to the picture

The Women's Health Initiative, or WHI, profoundly shaped the hormone-therapy discussion. It studied particular oral regimens in women whose average age was about 63. Its estrogen-plus-progestogen trial involved women with a uterus; its estrogen-alone trial involved women after hysterectomy. These were separate populations, not a direct test of adding or removing a progestogen. [8]

Long-term breast-cancer results differed. The combined regimen was linked to more breast cancers, without a clear difference in deaths from breast cancer. The estrogen-alone trial found fewer breast cancers and fewer breast-cancer deaths. Neither result turns estrogen into a cancer-prevention treatment, and neither applies unchanged to every modern formulation.

The studies remain relevant, alongside their limits. Changing the warning format did not create a new large trial proving that all oral hormone therapy prevents chronic disease. [17]

Heart health, memory and longer life

Earlier treatment may affect blood vessels differently. In ELITE, estradiol slowed thickening of a neck-artery wall when started nearer menopause. The result concerned an imaging measurement; it did not prove prevention of heart attacks. A later WHI analysis also suggests that cholesterol and broader cardiovascular health deserve attention alongside age. [9] [10]

The evidence for memory is similarly nuanced. KEEPS-Cog studied women soon after menopause and found no improvement in the cognitive tests with hormone therapy. Later follow-up of a returning subset did not identify a cognitive advantage either. A large 2026 observational study found lower dementia rates among hormone users, but could not separate the effect of treatment from all the ways those women differed from nonusers. [11] [12] [16]

Over roughly 18 years of WHI follow-up, including years after treatment ended, overall mortality was similar between the hormone and placebo groups. Younger starters had encouraging signals in some analyses. A large Danish observational study also found no increase in mortality among its selected hormone users. These findings help inform the discussion; they do not establish a general prescription for longer life. [14] [15]

Clinical guidance therefore distinguishes treating menopausal symptoms from prescribing hormones primarily to prevent heart disease or dementia. The latter benefits remain unproven, even when treating symptoms is a good choice. [7] [13]

A useful consultation starts with your priorities

At Healthy Longevity Clinic, our approach to evaluating evidence begins with the benefit you want to notice. Fewer night sweats, more comfortable intimacy and a bone-health plan raise different treatment questions.

Bring the symptoms that matter most, your medical and family history, and your questions about hormonal and nonhormonal options. The discussion should explain the proposed formulation, route, protection of the uterine lining when needed, and how you will judge whether treatment is helping.

Menopause symptoms deserve attention. The value of a more individualized approach is a choice that fits your life, with a plan to reassess as your symptoms and health change.